Latest news for GelStat (OTC:GSAC) Stock

GelStat Corp is a consumer healthcare company operating in the USA. It is engaged in the development and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's lead product is Gelstat Migraine, which is a patented OTC homeopathic drug for use as a first-line, acute treatment for migraine and migraine-like headaches. The Gelstat Migraine is developed to provide acute relief from headache pain as well as other symptoms associated with a migraine. The other products of the company include CHEWS 2 LOSE, which is a diet aide in the form of an all-natural appetite suppressant gum; All Natural Speed which targets specific quick-fix energy user groups; and GelStat Sleep, which provides relief from sleep disorders and their associated symptoms.

GelStat Corp

GelStat

<a href="https://www.globenewswire.com/Tracker?data=Qt_o9kffufL9OLsFFGWE_BkDC4EttnxHDjvSREdDqFA3lf-VefqpIoAVcxzykfQlKG2fi2cBaHtaoVX-MncwsOaps5qgyT8wb9D14CRmUOU=" target="_blank">GelStat Corporation</a>&nbsp;(&quot;GelStat&quot; or the &quot;Company&quot;) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GSAC#OTC">GSAC</a>), a development stage company currently focused on the research, development, and marketing of engineered solutions for the industrial security and clean energy industries, today announced that its&nbsp;<a href="https://www.globenewswire.com/Tracker?data=S1OopHxgED-xLJ2_tWVXE39T0Azebzn7L5-1fU6PfxEJH8GwQc3tL1p-NkyJV8CZR-tM9sSeOtLP8JveQQ8uTCvvzCUfUaDzYfj5YRvYdYiyXx24ataeNR0dLo4Ayv3WcEvJ4G_JHAPyFCYeyYHpE5lJbwugJ8sDc7arm_bIE1iey1ds7IPMkV96KQEGnfVOqoz8iVgidvK3E0ajnUyopoul4f5UeoKuVWjIHY0ICIM=" target="_blank">recently formed</a>&nbsp;subsidiary, GSAC Engineering (&quot;GSACe&quot;), has concluded the purchase of certain key intellectual property assets from Duos Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) (&quot;Duos&quot;).

Comments

GelStat

News

Latest news for GelStat (OTC:GSAC) Stock

Tuesday, September 12, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga